Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1633 1645 1646 1647
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18682785 | READY TO USE COMPOSITIONS OF CETRORELIX ACETATE | Non-Final OA | CITIBANK, N.A. |
| 18703963 | COMBINATION OF HUMAN NATURAL KILLER CELLS AND MACROPHAGES FOR CANCER THERAPY | Non-Final OA | The Regents of the University of California |
| 18281532 | TRANSPLANTED CELL PROTECTION VIA MODIFIED Fc RECEPTORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18312653 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | Non-Final OA | Eli Lilly and Company |
| 18565668 | NOVEL TARGETS FOR ENHANCING ANTI-TUMOR IMMUNITY | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18568011 | DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATING DERMATOMYOSITIS (DM) | Non-Final OA | Alexion Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy